- Home
- MRM vs EVOK Comparison
MRM vs EVOK Comparison
Compare MRM & EVOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MRM | EVOK |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Japan | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.8M | 18.4M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | MRM | EVOK |
|---|---|---|
| Price | $2.05 | $10.96 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 88.8K | 30.4K |
| Earning Date | 05-22-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $55,915,220.00 | $14,424,652.00 |
| Revenue This Year | N/A | $58.96 |
| Revenue Next Year | N/A | $57.99 |
| P/E Ratio | $51.31 | ★ N/A |
| Revenue Growth | 12.79 | ★ 67.40 |
| 52 Week Low | $0.34 | $1.94 |
| 52 Week High | $4.45 | $10.99 |
Technical Indicators
Market Signals| Indicator | MRM | EVOK |
|---|---|---|
| Relative Strength Index (RSI) | 46.23 | 84.79 |
| Support Level | $2.02 | $10.66 |
| Resistance Level | $2.33 | $10.99 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.01 | -0.19 |
| Stochastic Oscillator | 22.22 | 89.69 |
Price Performance
Historical ComparisonAbout MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.